Document is current
Any future updates will be listed below
-
Authors
Diociasi, Andrea
Pravatà , Emanuele https://orcid.org/0000-0002-5225-2993
Carmisciano, Luca
Kiersnowski, Oliver C.
Michele, Iester
Gunnewiek, Kevin Klein
Lorenzini, Luigi
Gualco, Lorenzo
Pardini, Matteo
Roccatagliata, Luca
Zecca, Chiara
Gobbi, Claudio
Guidotti, Roberto
Chincarini, Andrea
-
Funding
Funding for this research was provided by:
Velux Stiftung
Ente Ospedaliero Cantonale
Schweizerische Multiple Sklerose Gesellschaft
- License Information
-
More Information
Article History
Received: 19 January 2026
Revised: 7 April 2026
Accepted: 30 April 2026
First Online: 5 June 2026
Declarations
:
: This study was approved by the local Ethics Committee of Canton Ticino, Switzerland (Ref. 2017-00814; CE3224; date of approval: 24.02.2017).
: Written informed consent was obtained from all participants.
: EP received compensation for speaking activity and consulting fees unrelated to the present work from Bayer and Sanofi. CZ and CG have the following disclosure: Ente Ospedaliero Cantonale (employer) received compensation for speaking activities, consulting fees, or grants from AbbVie, Alexion, Almirall, Biogen, Bristol Myers Squibb, Eisai, Lilly, Lundbeck, Merck, Merz, Neuraxpharm, Novartis, Organon, Pfizer, Pharmaticino, Roche, Sandoz, Sanofi, Spirig, Takeda, and Teva Pharma. LG and LR are members of the Scientific Editorial Board of European Radiology Experimental and, as such, have not participated in the selection or review processes for this article.
